Literature DB >> 23763571

Increased levels of circulating arginase I in overweight compared to normal weight adolescents.

Christian Jung1, Hans R Figulla, Michael Lichtenauer, Marcus Franz, John Pernow.   

Abstract

BACKGROUND AND AIMS: Overweight and the metabolic syndrome have become major problems, especially in children and adolescents. Obesity at a young age increases the risk for cardiovascular diseases and diabetes mellitus later in life. An early event in the development of cardiovascular disease is endothelial dysfunction which is found in obese young individuals. Increased activity of the enzyme arginase has been described as a central mechanism for endothelial dysfunction, especially in patients with diabetes mellitus. The aim of the study was to determine plasma levels of arginase in overweight adolescents.
METHODS: Sixty-six male German adolescents (age: 15.2 ± 1.1 years old) were included. Thirty-one of them were overweight (>90th age-specific weight percentile). Plasma arginase I and tumor necrosis factor alpha (TNFα) were determined. In addition, clinical data were recorded and anthropometrical measurements of obesity were performed.
RESULTS: Overweight adolescents had a higher systolic blood pressure, lower high-density lipoprotein and increased levels of high-sensitive C-reactive protein (CRP). Circulating arginase I was elevated in overweight adolescents (95.8 ± 68.2 ng/ml) compared to normal weight adolescents (39.3 ± 26.9 ng/ml, p < 0.001) and correlated with markers of obesity. There was no difference between the two groups regarding TNFα.
CONCLUSIONS: We demonstrate that arginase I levels are increased in obese adolescents. Knowing the important role for arginase in endothelial dysfunction, elevated levels of arginase I may represent a link between obesity, endothelial dysfunction and related comorbidities.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adolescents; arginase; cardiovascular risk factors; cytokines; obesity; overweight

Mesh:

Substances:

Year:  2013        PMID: 23763571     DOI: 10.1111/pedi.12054

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  5 in total

1.  Arginase inhibition prevents the development of hypertension and improves insulin resistance in obese rats.

Authors:  Kelly J Peyton; Xiao-Ming Liu; Ahmad R Shebib; Fruzsina K Johnson; Robert A Johnson; William Durante
Journal:  Amino Acids       Date:  2018-04-27       Impact factor: 3.520

2.  Obesity-induced vascular dysfunction and arterial stiffening requires endothelial cell arginase 1.

Authors:  Anil Bhatta; Lin Yao; Zhimin Xu; Haroldo A Toque; Jijun Chen; Reem T Atawia; Abdelrahman Y Fouda; Zsolt Bagi; Rudolf Lucas; Ruth B Caldwell; Robert W Caldwell
Journal:  Cardiovasc Res       Date:  2017-11-01       Impact factor: 10.787

Review 3.  Arginase as a Critical Prooxidant Mediator in the Binomial Endothelial Dysfunction-Atherosclerosis.

Authors:  Luiza A Rabelo; Fernanda O Ferreira; Valéria Nunes-Souza; Lucas José Sá da Fonseca; Marília O F Goulart
Journal:  Oxid Med Cell Longev       Date:  2015-05-04       Impact factor: 6.543

4.  Arginase promotes endothelial dysfunction and hypertension in obese rats.

Authors:  Fruzsina K Johnson; Kelly J Peyton; Xiao-Ming Liu; Mohammed A Azam; Ahmad R Shebib; Robert A Johnson; William Durante
Journal:  Obesity (Silver Spring)       Date:  2014-12-31       Impact factor: 5.002

Review 5.  Obesity-Associated Myeloid Immunosuppressive Cells, Key Players in Cancer Risk and Response to Immunotherapy.

Authors:  Maria Dulfary Sanchez-Pino; Linda Anne Gilmore; Augusto C Ochoa; Justin C Brown
Journal:  Obesity (Silver Spring)       Date:  2021-02-22       Impact factor: 9.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.